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Abstract
Background: Tuberculosis (TB) accounts of much of the morbidity and mortality associated with HIV. We evaluate the cost-
effectiveness of different strategies to actively screen for TB disease in HIV positive individuals, where isoniazid preventative
therapy (IPT) is given to those screening negative, and use value of information analysis (VOI) to identify future research
priorities.
Methodology/ Principal Findings: We built an individual sampling model to investigate the costs (2010 US Dollars) and
consequences of screening for TB, and providing TB treatment or IPT in adults testing HIV positive in Sub-Saharan Africa. A
systematic review and meta-analysis was conducted to assess performance of the nine different TB screening strategies
evaluated. Probabilistic sensitivity analysis was conducted to incorporate decision uncertainty, and expected value of
perfect information for the entire model and for groups of parameters was calculated. Screening all HIV infected individuals
with sputum microscopy was the least costly strategy, with other strategies not cost-effective at WHO recommended
thresholds. Screening those with TB symptoms with sputum microscopy and CXR would be cost-effective at a threshold
ICER of $7,800 per quality-adjusted life year (QALY), but associated with significant uncertainty. VOI analysis suggests further
information would be of value.
Conclusions/ Significance: Resource-constrained countries in sub-Saharan Africa wishing to scale up TB preventative
services in their HIV infected populations should consider expanding laboratory facilities to enable increased screening for
TB with sputum microscopy, whilst improved estimates of the TB prevalence in the population to be screened are needed,
as it may influence the optimal strategy.
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Introduction
Tuberculosis (TB) and human immunodeficiency virus (HIV)
together pose a immense challenge to health services in sub-
Saharan Africa, where over 22 million people are living with HIV
[1]. TB is the commonest cause of mortality and morbidity in HIV
infected individuals [2,3], even after initiation onto highly active
antiretroviral treatment (HAART) [4,5]. Whilst the incidence of
TB is lower in those on HAART than those not on HAART [6,7]
and falls with time on HAART [4,8], it still remains higher than
that found in HIV negative populations [9]. Importantly, the
higher incidence of TB in the initial months of initiating HAART
[4,8] is felt partly to be a consequence of active TB not being
detected through routine screening [10].
HIV infected individuals are at increased risk of active TB as a
consequence of reactivation of latent TB infection (LTBI) [3,11] or
from recent infection with Mycobacterium tuberculosis rapidly
progressing to active disease. Isoniazid preventative therapy (IPT)
reduces this risk, which in combination with increased case
detection of active TB is essential to impact on TB control and
improve outcomes in HIV positive individuals [12,13]. In view of
this the WHO’s ‘‘Three Is’’ policy of intensified case finding (ICF),
IPT, and infection control, recommends all individuals testing
HIV positive in sub-Saharan Africa be screened for active TB
disease, and if no evidence found, receive IPT with or without
prior tuberculin skin testing [14]. Despite this only 9% of HIV
infected individuals are actively screened and 3% offered IPT [15],
partly as a consequence of the resource requirements needed to
implement these interventions [16].
There has been considerable research comparing the diagnostic
accuracy of different TB screening strategies [17–26], but still no
clear consensus on the most appropriate approach for ICF that
takes into account both the decisions of starting TB treatment or
initiating IPT. ICF and IPT have both been shown to be a cost-
effective intervention in sub-Saharan Africa [27–31], however,
previous studies have not considered the combined costs and
consequences of implementing both interventions in conjunction,
nor investigated alternate screening strategies. We therefore
sought to evaluate the cost-effectiveness of simple TB screening
strategies that could be implemented, where HIV positive
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30457individuals are either diagnosed with TB or started on IPT. We
evaluate a variety of strategies for which comparative cost-
effectiveness data is presently unavailable and for which
naturalistic trials would be difficult to undertake, and use value
of information (VOI) analysis to identify future research priorities
[32].
Methods
Analytic Overview
We used an individual sampling model (ISM) to evaluate the
incremental cost-effectiveness of nine TB screening strategies. An
ISM was chosen to track individuals’ histories and keep the model
structure to a manageable size, which would not have been
possible under the homogeneity assumption of Markov models
[33]. The model evaluated a hypothetical population of individ-
uals aged over 16 years testing HIV positive at health centres in
sub-Saharan Africa. Cost per quality adjusted life year (QALY)
was the primary outcome, and costs adjusted for inflation to 2010
US Dollars using a gross domestic product (GDP) deflator [34], as
recommended for economic evaluations in resource-constrained
settings [35]. The time horizon was two years, the duration of
benefit of IPT [36], and cycle length one month. The public health
provider perspective was chosen, and an annual discount rate of
3% applied to both costs and health effects [35]. The model was
built using TreeAge Pro 2009 (TreeAge Software, Williamstown,
MA).
Screening strategies
Figure 1 shows the nine TB screening strategies investigated.
The strategies use either one or a combination of: symptom
screening; sputum microscopy for acid-fast bacilli; or chest
radiography (CXR). For symptom screening the classical symp-
toms of TB (cough, fever, night sweats or weight loss) are
commonly reported among TB patients [21,25]. We investigated
screening for the presence of: chronic cough (Strategy 1); any one
of the classical symptoms (Strategy 2); or two or more of the
classical symptoms (Strategy 3). Four strategies used either CXR
or sputum microscopy. We considered screening all individuals
irrespective of whether they had any TB symptoms, (Strategies 4
[CXR] and 5 [sputum microscopy]). We also considered screening
only individuals with TB symptoms (TB suspects), (Strategies 6
[CXR] and 7 [sputum microscopy]). Finally, we considered
strategies using both CXR and sputum microscopy in TB suspects.
Sputum microscopy could be performed in all TB suspects and if
negative CXR performed (Strategy 8); conversely, CXR could be
performed first and sputum microscopy in those with negative
findings on CXR (Strategy 9).
The Model
Figure 2 describes how the screening strategy classifies
individuals into one of four groups, those screening positive who
either had TB disease (true positive) or not (false positive), and
those screening negative who either did not have TB disease (true
negative) or had TB disease (false negative). A Markov model then
simulates treatment related costs and outcomes for the four groups
(Figures S1, S2, S3, S4). Those without active TB, true negatives
and false positives, may or may not have LTBI. We therefore used
separate health states to account for their differing utilities and
subsequent risk of developing active TB.
Individuals screening positive for TB were given 6 months of
anti-TB treatment and those screening negative were given 6
months of Isoniazid (INH) [37]. The adverse consequences of
treatment were also modelled [38]. Those with active TB who
successfully completed TB treatment were assumed not to be at
risk of recurrence in the immediate future. Those falsely started on
TB treatment (false positive) were assumed not to be at risk of
developing TB either during or after treatment. Those correctly
Figure 1. Description of the nine screening strategies.
doi:10.1371/journal.pone.0030457.g001
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assumed to be at risk of developing active TB during their IPT
course, their risk reduced after completion of IPT [39], whilst
those without LTBI were assumed not to be at risk of developing
active TB. Individuals who had active TB not diagnosed (false
negative) experienced the disutility of active TB disease, but we
allowed for the possibility that they might seek care later. We
assumed that those who sought care later would undergo the same
screening strategy and the outcome of screening was independent
of an individual’s prior screening outcome. Individuals with active
TB were at risk of TB related mortality, until completion of TB
treatment, whilst all individuals were at risk of non-TB related
mortality. The costs and benefits of HAART were not considered
and we assumed there was no HIV disease progression, during the
2 years the model was run.
Input parameters for Model
Data sources. We carried out several formal systematic
reviews to identify model parameters, and limited our search to
studies done in resource-constrained settings. We performed a
meta-analysis of data extracted if possible, if not we used data from
the most recent meta-analysis, and if not present we used data
from relevant studies. Table 1 shows the input parameters used in
the model. The low and high values represent the reported 95%
confidence interval, when not available they represent the lowest
and highest values from the range of studies found.
Transition probabilities. Sensitivities and specificities of the
TB screening strategies were pooled using Meta-DiSc version 1.4
(Unit of clinical biostatics, the Ramo y Cajal Hospital, Madrid,
Spain). Random effects model was used to pool values because of
significant between-study heterogeneity. The prevalence of TB in
HIV populations was taken from a recent meta-analysis [40],
whilst the prevalence of LTBI in sub-Saharan Africa was extracted
from a study done by Corbett et al [41]. There was no data
available on the risk of a fatal event in those who experienced
adverse events on TB treatment. As the treatments have similar
side effect profiles [42], we assumed that the ratio of the risk of
fatal events, subsequent to an adverse event, with TB and LTBI
treatment was proportional to the ratio of the risk of adverse events
with TB and LTBI treatment. We found no applicable data
regarding uptake and subsequent loss to follow-up (LTFU) from
ICF and IPT programmes. We therefore assumed all those
screened would initiate and complete their respective treatments,
however, this was further investigated in the sensitivity analysis.
The risk of TB in those with LTBI, pre- and post- IPT, was
extracted from a recent study by Golub et al [43]. As a
consequence of lack of relevant data we assumed that TB and
non-TB related mortality in individuals with early HIV disease not
on HAART is comparable to mortality in individuals with more
advanced HIV disease but receiving the benefits of HAART. The
risk of TB related mortality for individuals on TB treatment was
extracted from a recent meta-analysis [39]. For non-TB related
mortality in HIV populations, data was extracted from a large
study that presented findings from a number of HIV treatment
centres across sub-Saharan Africa [44]. The mortality rate for
those in whom HAART had been initiated with early HIV disease
and who survived the first year of treatment was used. We assumed
that this risk of death included the risk from non-HIV related
causes, as this was the endpoint in their study.
Costs of screening and care. The direct medical costs
accrued by the organisation administering the screening, providing
TB treatment or IPT, and managing adverse effects of treatment
were considered. We assumed the screening strategy would be
integrated within existing HIV and TB services at no additional
start-up costs as these services are already in existence. However,
we considered there would need to be some scale-up of services in
terms of staffing required to implement the program. The cost of
the screening strategies was derived from data published by the
Disease Control Priorities Project (DCPP), a description of
methods used has been published [45], and are in accordance
with WHO costing guidelines [35]. Costs for the World Bank sub-
Saharan Africa region were used to aid generalisability of findings.
The cost of the screening strategy included cost of a clinic visit
and the additional cost of any investigations. The cost of a clinic
visit consisted of the long-run capital costs and labour costs
(15 minutes of healthcare worker and 15 minutes of a registered
nurse). For investigations, costs include overhead, equipment,
consumables and labour [45]. For strategies where sputum smears
were done, costs were calculated for two specimens as the value of
the third sputum is low [46]. For strategies incorporating a CXR
the cost of an outpatient visit in a secondary care hospital and
15 minutes of a physician labour cost instead of a nurse was used
to reflect the need for a clinician to interpret the film. For
strategies involving a combination of screening methods, the cost
of the whole algorithm was calculated by adding the cost for each
screening step. As only a proportion would proceed to the next
screening method, only a proportion of the cost was added. We
assumed 75% of participants would proceed onto subsequent
screening method if suspected and not diagnosed; this was based
on attrition rates reported by Shrestha et al [30]. To ensure
comparability between costs of providing TB treatment and IPT,
and associated adverse events, data was extracted from the same
study and represent the full program costs inclusive of drugs,
labour and overheads [30]. The cost of TB treatment quoted was
for an 8-month course. The WHO recommends a course of 6
months duration, as the additional two months provide no benefit
[37]. We assumed that the monthly cost was constant and limited
all individuals to 6 months treatment. There was no published
data available for the costs associated with adverse reactions to TB
treatment. As IPT and TB treatment have similar side-effect
profiles [42], we assumed the costs to be equivalent.
Health related Quality of life. We used utility scores from
data published by Lara et al [47] for their pre-HAART cohort, as
this is considered the only valid utility data presently available
[48]. We classified individuals based on their WHO HIV clinical
stage [49], as was done in previous modelling exercises in this area
[27,30]. Utility scores associated with experiencing an adverse
reaction to TB or LTBI treatments are similar [42] and have
previously been assumed to be equivalent to WHO stage 4
[27,30]. We made assumptions for utility scores for states
associated with LTBI and post LTBI and TB treatment using
evidence from the literature. Individuals with active TB have
lower utility scores than individuals with LTBI [50,51], and
improve with treatment [51]. Individuals with LTBI have lower
utility scores than those never previously infected [51], and show
no change subsequent to treatment. The base case values assumed
were chosen to reflect this and ranges for probabilistic analysis
chosen to ensure no overlap with utility values for states preceding
or arising from it, and wide to reflect the uncertainty underlying
these assumptions.
Sensitivity analysis and Value of Information. Probabilistic
sensitivity analysis (PSA) was performed using Monte Carlo
simulation (MCS) to take into account uncertainty in individual
patient outcomes and uncertainty in parameters values [52]. For
each of the strategies we ran 10,000 model runs, with 10,000
individuals sampled for each run. Distributions used to represent
parameter uncertainty were Beta for transition probabilities and
utilities, and Gamma for costs [52]. VOI analysis was used as an
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Parameter Base Low High Distribution Source
Transition probabilities
Strategy 1: Chronic cough.2 weeks
Sensitivity 0.440 0.399 0.482 Beta [17–26]
Specificity 0.810 0.802 0.818 Beta
Strategy 2: Any Classic symptom
Sensitivity 0.889 0.860 0.913 Beta [17,19–26]
Specificity 0.492 0.482 0.502 Beta
Strategy 3: Two or more Classic symptoms
Sensitivity 0.415 0.361 0.470 Beta [18,22,23,25]
Specificity 0.904 0.892 0.915 Beta
Strategy 4: CXR on all
Sensitivity 0.635 0.586 0.682 Beta [18,19,22,23,25,26]
Specificity 0.865 0.855 0.875 Beta
Strategy 5: Sputum on all [17–19,22,25]
Sensitivity 0.403 0.354 0.454 Beta
Specificity 0.990 0.986 0.993 Beta
Strategy 6: Symptom +/2 CXR
Sensitivity 0.684 0.581 0.776 Beta [19,22]
Specificity 0.800 0.785 0.815 Beta
Strategy 7: Symptom +/2 Sputum
Sensitivity 0.439 0.387 0.492 Beta [19,22,25]
Specificity 0.880 0.870 0.890 Beta
Strategy 8: Symptom +/2 Sputum +/2 CXR
Sensitivity 0.672 0.616 0.725 Beta [23,25]
Specificity 0.867 0.851 0.882 Beta
Strategy 9: Symptom +/2 CXR +/2 Sputum
Sensitivity 0.7580.791 0.659 0.840 Beta [19,22]
Specificity 0.776 0.806 Beta
TB prevalence 0.086 0.036 0.247 Beta [40]
LTBI prevalence 0.31 0.27 0.46 Beta [41]
Seeking care – Passive case finding 0.1985 0.0779 0.4512 Beta [77]
Adverse event on TB treatment 0.0032 0.0023 0.0044 Beta [78]
Fatal event on TB treatment given adverse event 0.0504 0.0033 0.1552 Beta Estimated
Adverse event on IPT 0.0023 0.0008 0.0090 Beta [60,79–81]
Fatal event on IPT given adverse event 0.0360 0.0009 0.1277 Beta [60]
Risk of TB in those with LTBI: Pre-completion of IPT 0.0057 0.0050 0.0066 Beta [43]
Post-completion of IPT 0.0009 0.000017 0.0061 Beta [43]
Death in treated TB patients 0.0145 0.0047 0.0246 Beta [39]
Death in untreated TB patients 0.0488 0.0392 0.0582 Beta [82,83]
Death from non-TB 0.00022 0.000067 0.00078 Beta [44]
Cost Parameters (2010 US Dollars)*
TB treatment** $78.97 $60.42 $111.74 Gamma [30,84,85]
IPT** $21.08 $10.55 $31.63 Gamma [30]
Adverse effects of IPT and TB treatment** $344.95 $115.22 $566.74 Gamma [30,86]
Strategy 1–3 $3.08 $1.43 $9.51 Gamma [45]
Strategy 4 $16.07 $11.74 $43.91 Gamma [45]
Strategy 5 $5.24 $2.90 $12.28 Gamma [45]
Strategy 6 $15.14 $10.23 $42.44 Gamma [45]
Strategy 7 $7.02 $3.62 $18.72 Gamma [45]
Strategy 8 $13.45 $8.30 $35.24 Gamma [45]
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[53], to quantify the value of future research.
Determining the value of future research in resource-con-
strained settings provides an approach to aid efficient use of
limited research funding and direct research to answering
decisions faced by policy makers. PSA describes the uncertainty
surrounding the optimal decision and indirectly the probability
that the decision based on current information will be wrong.
There are consequences of making the wrong decision, either in
resources or health benefits forgone, which would be eliminated if
we had perfect information. However, further information comes
at a cost and is only valuable if it alters the optimal decision. VOI
quantifies the expected value of perfect information (EVPI) by
calculating the expected payoff if we had perfect information
compared to existing information [54]. The EVPI will be greater
when there is greater uncertainty around the optimal decision and
when for a given level of uncertainty our maximum willingness to
pay (WTP) threshold is higher [32,55]. If the EVPI is greater than
the cost of obtaining new information, then further research will
be valuable. However, EVPI analysis on its own does not indicate
what further information to obtain. To direct future research
requires expected value of perfect parameter information (EVPPI).
EVPPI analysis can be performed for any single parameter or
group of parameters within a model and is used to calculate how
much of the expected payoff, the expected value of perfect
parameter information (EVPPI), would come from having perfect
information on each of the selected input parameters. For
computational reasons we performed a one-level MCS with the
parameters of interest kept constant, whilst the remaining were
sampled from their distribution [32]. The parameters were
grouped based on how future research might be carried out. We
used Pearson’s correlation coefficient to investigate for the
presence of significant correlations between input parameters,
and performed multiple linear regressions for each of strategies’
net monetary benefit as the dependent variable and the sampled
input parameter as the independent variable. Provided that the
randomly sampled input parameters are not significantly corre-
lated and the net benefit is a multi-linear function of the
parameters a one-level MCS can be performed [56,57].
Sensitivity analysis: Alternative model structures. We
investigated the impact of loss to follow up (LTFU) on the optimal
strategy. Evidence suggests a significant proportion of patients
starting either IPT or TB treatment may be LTFU prior to
starting treatment, during the initial phases of treatment, or during
the latter stages of treatment [58–62]. Completion rates range
from 55% to 86% [43,60,62,63] and 80% to 88% [58,59,61],
respectively. We therefore assumed the risk of LTFU prior to
initiating therapy was equal to that subsequent to initiating
therapy. However, we assumed that this risk could differ between
those starting IPT and those starting TB treatment. We also
assumed those LTFU who had active TB could subsequently seek
care and those who had LTBI were at risk of developing active
TB. We ran the model investigating a range of completion rates,
100%, 80%, 60% or 20%, for IPT and TB treatment.
Decision rules. The lack of cost-effectiveness data
comparing these screening strategies, especially in the context of
IPT, implies knowing the least costly strategy is essential. The
WHO recommends in resource constrained countries
interventions where the value of a unit of health gain is less than
the gross national income (GNI) per capita as being ‘very cost-
effective’, values less than three times being ‘cost-effective’ [64].
The GNI per capita inflated to 2010 for the sub-Saharan region is
2167 US Dollars [34,65], and therefore our maximum willingness
to pay (WTP) thresholds were 2167 US Dollars (l1) and 6500 US
Dollars (l2).
Results
The findings of the base-case analysis are shown in Table 2. The
mean cost to screen and provide either TB treatment or IPT
ranged from $169 to $325 per individual. The least costly strategy
involved screening with sputum microscopy (Strategy 5), and the
most effective strategy involved screening for the presence of any
classical TB symptoms (Strategy 2). The incremental cost utility
analysis shows that Strategy 1 is strongly dominated, whilst
strategies 3, 4, 6 and 7 are weakly dominated and therefore none
of these strategies would be recommended in terms of cost-
effectiveness. If our willingness to pay for an extra QALY were
zero then Strategy 5 would be the most cost-effective. In
comparison to Strategy 5 the other strategies would not be
considered cost-effective at either of our threshold ICERs. Strategy
8 would be cost-effective at a threshold ICER of $7,800/QALY.
Strategy 9 becomes optimal at a threshold ICER of $13,600/
QALY and Strategy 2 at thresholds over $24,500/QALY.
Comparison of the effectiveness of the non-dominated strategies,
5, 8, 9 and 2, reveals 75.8%, 90.2%, 92.8% and 94.0% of
individuals with active TB will successfully complete TB
treatment, respectively, whilst 1.9%, 16.3%, 23.7% and 53.1%
Parameter Base Low High Distribution Source
Strategy 9 $17.24 $11.40 $47.35 Gamma [45]
Utility Parameters
Stage 2: -Well 0.63 0.60 0.65 Beta [47]
-LTBI/Post LTBI treatment 0.56 0.53 0.59 Beta Estimated
-Post TB treatment 0.49 0.46 0.52 Beta Estimated
Stage 3: -Active TB disease 0.39 0.37 0.42 Beta [47]
Stage 4: -Adverse effects of TB/LTBI drugs 0.15 0.13 0.17 Beta [47]
Parameter Base Low High Distribution Source
*Costs for screening strategies based on: Health clinic visit, $3.08 (1.43–9.51); Outpatient clinic visit, $4.61 (1.43–31.30); Health worker daily salary, $23.52 (17.59–56.62);
Nurse daily salary, $33.92 (25.65–82.90); Physician daily salary, $57.12 (42.74–137.77); Sputum microscopy $2.56 (1.78–3.25); CXR $11.46 (10.31–12.61).
**Total program cost inclusive of overheads, personnel and drugs. For TB treatment; low value represents Community-based care with up to 19 days hospitalization
[85]; base case value [85] and high value [84] represent hospital-based care with up to 60 days hospitalization.
doi:10.1371/journal.pone.0030457.t001
Table 1. Cont.
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respectively. In comparison to Strategy 5, the incremental cost for
an additional individual with active TB to successfully be treated
was $4,700, $12,100 and $74, 700 for strategies 8, 9 and 2,
respectively, whilst the incremental cost to prevent an additional
individual dying from active TB, or as a consequence of adverse
drug reactions to TB treatment or IPT, was $5,700, $11,000 and
$21,900, respectively.
Sensitivity analysis and Value of information
The optimal strategies are shown on a cost-effectiveness frontier
(CEAF). Cost-effectiveness acceptability frontiers provide a
method of representing the optimal decision at differing threshold
ICERs in the context of multiple alternatives [66]. Figure 3 shows
the CEAF and highlights that whilst Strategy 8 is the optimal
decision at the threshold ICER of $7,800/QALY, we are only
18% certain of this. At our very cost-effective (l1) and cost-
effective thresholds (l2), the probability that Strategy 5 is optimal is
0.96 and 0.58 respectively, the probability that Strategy 8 is
optimal is 0.01 and 0.15 respectively, the probability that Strategy
9 is optimal is ,0.01 and 0.09 respectively, whilst the probability
Strategy 2 is optimal is ,0.01 and 0.01 respectively.
We calculated the EVPI and EVPPI for current and future
populations [54], assuming an annual HIV incidence in sub-
Saharan Africa of 1.5 million [1], and a conservative estimate of 5
years for the lifetime of the decision problem. Figure 3 displays the
population EVPI (PEVPI) at increasing threshold ICERs, and
Table 3 shows the PEVPI and population EVPPI (PEVPPI) at our
two WTP thresholds. The PEVPI peaks at a threshold of about
$24,400/QALY, the point where the optimal strategy changes
from Strategy 9 to 2. The PEVPI at our two cost-effectiveness
threshold ICERs of l1 and l2 was about $2 million and $98
million respectively. The PEVPPI output suggests improving our
estimate of the prevalence of TB and LTBI in our target
population is likely to provide the greatest payoff. Further research
into the costs of the different screening strategies would be of more
value than further research into their diagnostic accuracy, whilst
further research in TB treatment is expected to provide more
value than research in IPT treatment.
We explored the effect of TB prevalence on the optimal decision
and value of further research. We re-ran the model keeping the
TB prevalence constant at 1%, 5%, 10% or 25%; Figure 4 shows
the CEAF and EVPI curves. As the true TB prevalence decreases
from 25% to 1%, the threshold ICER at which the other strategies
becomes optimal increases, whilst the value of further research at
our two threshold ICERs decreases. If the true TB prevalence
were less than 5%, none of the other strategies would be optimal at
threshold ICERs below $10,000/QALY.
Sensitivity analysis: Alternative model structures
We explored the effect of LTFU on the optimal decision.
Figure 5 shows the CEAF for a range of completion probabilities
for TB treatment and IPT. Strategy 5 remains optimal at
threshold ICERs up to $5,200/QALY irrespective of the
completion probabilities of IPT or TB treatment. The only
scenarios where Strategy 5 is not optimal at our cost-effective
Table 2. Findings from the base-case model.
Mean
Cost ($)
Mean
QALY’s
% of individuals
wrongly treated
for TB
% of individuals
with active TB
completing
treatment
Incremental
Analysis
Cost ($) QALYs $/QALY
$/Individual
Successfully
treated for
TB*
S/Death
averted**
Strategy 5
Sputum on all
169 1.135 1.9 75.8 - - - - -
Strategy 3
Two or more Classic symptoms
191 1.136 11.9 76.3 22.0 0.001 ED ED ED
Strategy 7
Symptom +/2 Sputum
207 1.137 14.3 77.9 16.1 0.001 ED ED ED
Strategy 4
CXR on all
221 1.142 15.4 88.7 13.5 0.005 ED ED ED
Strategy 1
Chronic cough.2 weeks
221 1.137 20.1 77.6 0.6 20.005 D D D
Strategy 8
Symptom +/2 Sputum +/2 CXR
225 1.143 16.3 90.2 4.3 0.001 7,775 4,656 5,675
Strategy 6
Symptom +/2 CXR
241 1.143 22.8 90.1 16.9 ,0.001 ED ED ED
Strategy 9
Symptom +/2 CXR +/2 Sputum
251 1.144 23.7 92.8 9.3 0.001 13,552 12,145 11,001
Strategy 2:
Any Classic symptom
325 1.147 53.1 94.0 73.9 0.003 24,376 74,710 21,870
QALY: quality-adjusted life year.
D: dominated strategy (one or more alternative strategies are cheaper and more effective).
ED: extended dominance (one or more alternative strategies more expensive but have lower ICER).
$ 2010 US Dollars.
*Incremental cost per additional individual with active TB who successfully completes TB treatment course.
**Incremental cost per death averted (either from active TB, adverse drug reaction to TB treatment or IPT).
doi:10.1371/journal.pone.0030457.t002
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doi:10.1371/journal.pone.0030457.g003
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and IPT completion is 100%, or where TB completion falls below
20% and IPT completion is higher than 80%. In these scenarios,
either strategy 2 or 4 were optimal. Where completion
probabilities of IPT and TB treatment are comparable, strategy
5 remains optimal at our cost-effective threshold (l2).
Discussion
We modelled the costs and consequences of different TB
screening strategies that could be employed if all individuals
testing HIV positive in sub-Saharan Africa were to be screened
for active TB prior to starting IPT. The findings suggest the least
costly strategy involves screening with sputum microscopy
(Strategy 5). At the WHO threshold ICERs, the other strategies
evaluated would not be considered cost-effective in comparison.
The mean cost per individual screened and treated for either on
TB or LTBI with Strategy 5 was $169, and comparable to
previous findings [29–31]. The VOI analysis suggests further
research would be of value, although possibly only at our higher
threshold ICER (l2). The value of knowing the true TB
prevalence in the population to be screened is especially
important. Not only does it impact on our optimal decision, it
also affects whether subsequent research into the other param-
eters would be cost-effective (Figure 3).
The model considers screening for active TB and providing IPT
as a single decision problem. Whilst screening strategies with
higher sensitivities are more effective, as greater proportion of
individuals with active TB successfully complete treatment, it is
their relative specificity that determined cost-effectiveness. The
majority of the costs incurred are as a result of providing either TB
treatment or IPT. As providing TB treatment is about four times
as costly as IPT, falsely starting TB treatment incurs considerable
cost with no benefit. Screening for the presence of any of the
classical symptoms of TB, Strategy 2, has been shown to be a
reliable method of excluding TB prior to starting IPT [67],
especially as there are concerns that starting INH in individuals
falsely excluded for TB may increase the burden of multi-drug
resistant TB [68]. The model suggests that whilst this was the
optimal symptom based screening strategy and the most effective,
it would not be cost-effective at our threshold ICERs.
Investigating TB suspects with sputum microscopy and/or
CXR was cost-effective, albeit at higher threshold ICERs, only if
both investigations were performed. As with previous findings, the
more cost-effective option would be to screen symptomatic
individuals with sputum followed by CXR (Strategy 8) rather
than CXR followed by sputum (Strategy 9) [28,69]. The
incremental analysis suggests Strategy 8 is cost-effective at a
threshold ICER of US$ 7,800/QALY. Although, at this threshold
ICER we are only 18% confident this would be the optimal
decision, whilst we are more or less 100% confident choosing
Strategy 5 is the least costly strategy. Whilst there is uncertainty
about the role of CXR in the screening for TB in HIV infected
individuals [70–72], the model suggests CXR does have value but
only in conjunction with sputum microscopy in TB suspects.
The underlying TB prevalence has a deterministic effect on the
optimal decision. If the true TB prevalence in the population
screened is lower than 5%, we are almost certain that the optimal
decision would be to screen everyone with sputum microscopy,
with alternate strategies cost-effective at very high threshold
ICERs. At prevalences higher than 10%, other strategies become
cost-effective at affordable levels. In practice the prevalence of TB
varies on the setting where ICF is employed [40] and therefore it
may be rational to employ different screening strategies depending
on the setting.
We explored the consequences of LTFU and found Strategy 5
remains optimal at threshold ICER’s up to $5,200/QALY
irrespective of the degree of LTFU. If, as the literature suggests
[43,58–63], LTFU in those started on IPT and TB treatment is
comparable, Strategy 5 remains optimal at our higher threshold
ICER (l2). The only scenario in which LTFU alters the optimal
strategy at our higher threshold ICER (l2) is where LTFU
amongst those started on TB treatment is high ($60%) and LTFU
amongst those started in IPT is low (#20%). We made the
assumption that LTFU was dependent on the treatment given.
However, there may be greater attrition for strategies that require
more clinic visits. This is likely to have a greater impact on
Strategies 6–8 as they require more clinic visits.
Recently it has been highlighted that the lack of operational
research in tuberculosis may be a consequence of determining
what the research priorities are [73]. VOI analysis achieves this by
ensuring future research is directed to answering decision
problems faced by policy makers. It offers significant advantages,
for example, it draws attention to the finding that further research
into the costs of the screening strategies offers more value than
research into their diagnostic accuracy. It informs us that whist
there are concerns regarding the validity of the available utility
data [48], further research into determining utility scores for HIV
positive individuals with TB or LTBI will have little impact on this
decision. This is one of the first studies to use VOI analysis in
resource-constrained settings, and should encourage its continued
use.
The analysis was carried out in accordance with WHO
guidelines [35]. We undertook a formal systematic review and
Table 3. Findings from population EVPI and EVPPI analysis.
PEVPI/PEVPPI at WTP=l1
(Million $)
PEVPI/PEVPPI at WTP=l2
(Million $)
Base-case analysis 2.0 97.7
Cost of Screening Strategy 1.2 12.2
Sensitivity and Specificity of Screening Strategy ,0.1 8.9
Prevalence of active TB and latent TB infection 1.7 51.5
TB treatment costs and outcomes 0.7 9.0
IPT treatment costs and outcomes 0.4 0.4
Health state utilities 0.0 0.0
$ 2010 US Dollars.
doi:10.1371/journal.pone.0030457.t003
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and used cost data standardised to sub-Saharan Africa to aide
generalisability. The main limitations are that it uses a static model
and fails to consider consequences of developing INH resistance.
Whilst the model does not consider the consequences of ICF and
IPT on TB transmission, evidence suggests it is the HIV negative
TB cases that drive TB prevalence [74], and therefore unlikely the
TB screening strategies will have differing levels of impact on TB
prevalence. Any impact is unlikely to alter the fact that screening
everyone with sputum microscopy will remain optimal, as it is
smear positive TB that drives TB transmission. We did not
consider the development of INH resistance in those falsely
excluded for active TB. Currently, the evidence suggests no
increased risk [75,76]. If future research reveals increased risk,
strategies associated with higher sensitivities are likely to be cost-
effective at lower thresholds than found in the model.
Figure 4. CEAF and PEVPI curves at different TB prevalence.
doi:10.1371/journal.pone.0030457.g004
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30457The low sensitivity of sputum microscopy in HIV infected
individuals is felt to limit its use [72], but its high specificity makes
it a cost-effective option for programs wishing to scale up both ICF
and IPT in their HIV infected population, especially if the true TB
prevalence is below 5%. In settings where the underlying TB
prevalence is known to be higher, it is likely that a combination of
symptom screening and diagnostic procedures would be cost-
effective.
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